Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Manuel Ruíz-Borrego"'
Autor:
Ann H. Partridge, Samuel M. Niman, Monica Ruggeri, Fedro A. Peccatori, Hatem A. Azim, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B. Sætersdal, Judith R. Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E. Lee, Janice M. Walshe, Manuel Ruíz-Borrego, Halle C.F. Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L. Smith, Teresa Ferreiro, Karin Ribi, Kathryn Ruddy, Roswitha Kammler, Sarra El-Abed, Giuseppe Viale, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber, Olivia Pagani
Publikováno v:
New England journal of medicine, 388(18), 1645-1656. Massachussetts Medical Society
Background Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Methods We conducted a single-group trial in which we
Autor:
Antonio Llombart-Cussac, Javier Cortés, Andrea Malfettone, Crina Popa, Miguel Sampayo-Cordero, Silvia Menéndez, Federico Rojo, Beatriz Bellosillo, Leonardo Mina, Ana Santaballa Bertran, Vanesa Quiroga, Alessandro Marco Minisini, Enrique Espinosa, Juan de la Haba, Lourdes Calvo, Begoña Bermejo, Meritxell Bellet, Joan Gibert, Laura Comerma, Manuel Ruíz-Borrego, Giuseppe Curigliano, Miguel Gil-Gil, José Manuel Pérez-García, Joan Albanell
Summary of all adverse events according to NCI-CTCAE version 4.0.3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72568bda800ffb38bd5bdf1659e5cc64
https://doi.org/10.1158/1078-0432.22489440
https://doi.org/10.1158/1078-0432.22489440
Autor:
Antonio Llombart-Cussac, Javier Cortés, Andrea Malfettone, Crina Popa, Miguel Sampayo-Cordero, Silvia Menéndez, Federico Rojo, Beatriz Bellosillo, Leonardo Mina, Ana Santaballa Bertran, Vanesa Quiroga, Alessandro Marco Minisini, Enrique Espinosa, Juan de la Haba, Lourdes Calvo, Begoña Bermejo, Meritxell Bellet, Joan Gibert, Laura Comerma, Manuel Ruíz-Borrego, Giuseppe Curigliano, Miguel Gil-Gil, José Manuel Pérez-García, Joan Albanell
Supplementary Table S1. Selection Criteria; Supplementary Table S2. Recruiting Sites, Principal Investigators, and Patient Numbers; Supplementary Table S3. Study Members; Supplementary Table S4. List of antibodies used for immunohistochemistry analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a7cea33a4c76d1718e21fd8603fcb7
https://doi.org/10.1158/1078-0432.22489431
https://doi.org/10.1158/1078-0432.22489431
Autor:
Antonio Llombart-Cussac, Javier Cortés, Andrea Malfettone, Crina Popa, Miguel Sampayo-Cordero, Silvia Menéndez, Federico Rojo, Beatriz Bellosillo, Leonardo Mina, Ana Santaballa Bertran, Vanesa Quiroga, Alessandro Marco Minisini, Enrique Espinosa, Juan de la Haba, Lourdes Calvo, Begoña Bermejo, Meritxell Bellet, Joan Gibert, Laura Comerma, Manuel Ruíz-Borrego, Giuseppe Curigliano, Miguel Gil-Gil, José Manuel Pérez-García, Joan Albanell
Purpose:To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond progression on prior palbociclib-based regimen in patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a3e1b98440fb1afb63e5afb596035ca
https://doi.org/10.1158/1078-0432.c.6532953
https://doi.org/10.1158/1078-0432.c.6532953
Autor:
Joan Albanell, José Manuel Pérez-García, Miguel Gil-Gil, Giuseppe Curigliano, Manuel Ruíz-Borrego, Laura Comerma, Joan Gibert, Meritxell Bellet, Begoña Bermejo, Lourdes Calvo, Juan de la Haba, Enrique Espinosa, Alessandro Marco Minisini, Vanesa Quiroga, Ana Santaballa Bertran, Leonardo Mina, Beatriz Bellosillo, Federico Rojo, Silvia Menéndez, Miguel Sampayo-Cordero, Crina Popa, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Scientia
Hormone receptor; Advanced breast cancer Càncer de mama avançat; Receptor hormonal Cáncer de mama avanzado; Receptor hormonal Purpose: To assess the efficacy and exploratory biomarkers of continuing palbociclib plus endocrine therapy (ET) beyond p
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Miguel Sampayo-Cordero, Trial Investigators, Duncan Wheatley, Marco Colleoni, Petra Tesarova, Pilar Zamora, Kepa Amillano, Steven Chan, Gianfilippo Bertelli, Jacques Medioni, Thierry Petit, Juan de la Haba, Vicente Caranyana, Joan Albanell, Peter Schmid, Mark Beresford, Andrea Malfettone, Francesco Atzori, Joaquín Gavilá, Saverio Cinieri, Vladimir Moiseyenko, Luigi Cavanna, Gemma Viñas, Vladimir Vladimirov, Maria Luque-Cabal, Mario Airoldi, Sonia Servitja, Elena Aguirre, Florence Dalenc, Jose Perez-Garcia, Santiago González, Purificación Martínez, Daniele Generali, Meritxell Bellet, Antonio Antón, Andreas Schneeweiss, Manuel Ruíz-Borrego, Antonio Llombart-Cussac, Serena Di Cosimo, Eduardo Martínez-de Dueñas, Laura Cortesi, Juan Cueva Bañuelos, Joseph Gligorov, Guzel Mukhametsina, Bohuslav Melichar, Javier Cortes, Joachim Bischoff, Maria Cazzaniga, Raquel Andres, Tatiana Barannikova, Juan Bayo, Andrew Wardley, Paul Cottu, Frederik Marmé, Miguel Gil-Gil
Publikováno v:
JAMA Oncology
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Banco de España
JAMA Oncol
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Banco de España
JAMA Oncol
Question Which is the optimal endocrine partner (fulvestrant vs letrozole) for cyclin-dependent kinase 4 and 6 inhibitor palbociclib in previously untreated, endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer? Findi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f4524ba8006b75028094e0a91d824eb
http://hdl.handle.net/11368/3017531
http://hdl.handle.net/11368/3017531
Autor:
Manuel, Ruíz-Borrego, Angel, Guerrero-Zotano, Begoña, Bermejo, Manuel, Ramos, Josefina, Cruz, Jose Manuel, Baena-Cañada, Beatriz, Cirauqui, Álvaro, Rodríguez-Lescure, Emilio, Alba, Noelia, Martínez-Jáñez, Montserrat, Muñoz, Silvia, Antolín, Isabel, Álvarez, Sonia, Del Barco, Elena, Sevillano, José Ignacio, Chacón, Antonio, Antón, María José, Escudero, Victoria, Ruiz, Eva, Carrasco, Miguel, Martín, A L, Moreno
Publikováno v:
Breast cancer research and treatment. 177(1)
GEICAM/2006-10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is superior to aromatase inhibitors alone in breast cancer patients receiving hormone adjuvant therapy
Autor:
Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruiz-Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M. Tolaney
Publikováno v:
Breast, Vol 72, Iss , Pp 103580- (2023)
Background: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2–) breast cancer. The non
Externí odkaz:
https://doaj.org/article/0fa5c73c7ab04a5990f87bbac59a8a3e
Autor:
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A. Jo Chien, Hope S. Rugo, Adam Brufsky, Michael Thirlwell, Maureen Trudeau, Ron Bose, José A. García-Sáenz, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Benjamin Schnappauf, Dieter Semsek, Christian F. Singer, Navid Foruzan, Daniel DiPrimeo, Leanne McCulloch, Sara A. Hurvitz, Carlos H. Barcenas
Publikováno v:
Breast, Vol 67, Iss , Pp 94-101 (2023)
Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for HER2-positive early-stage and metastatic breast cancer. Diarrhea is the most frequent side effect and the most common reason for early discontinuation. The phase
Externí odkaz:
https://doaj.org/article/59dce946fa4342e6b9fbbf464f2e5a40